Results 271 to 280 of about 3,310,854 (363)

Familial Frontal Fibrosing Alopecia Occurs Early in Daughters With Affected Mothers: A Case Report and a Review of the Literature

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Frontal fibrosing alopecia (FFA) is a form of cicatricial alopecia that is being increasingly diagnosed in recent years. It predominantly affects post‐menopausal women of various ethnic backgrounds, but cases have also been reported in pre‐menopausal women and rarely in men.
Adrienne Oxenham, Annabel Stevenson
wiley   +1 more source

Management of Patients with IBD and History of Cancer. [PDF]

open access: yesCancers (Basel)
Faggiani I   +10 more
europepmc   +1 more source

Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Background Mucous membrane pemphigoid (MMP) has a broad range of clinical manifestations, from relatively benign self‐limiting oral lesions to significant scarring (cicatrizing) of the oral, nasal and ocular tissues with severe functional impairment and morbidity.
Bronte Jeffrey   +9 more
wiley   +1 more source

Using Biologics to Reduce Long‐Term Corticosteroid Use in Pyoderma Gangrenosum: Real‐World Evidence From Two Centres

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a challenging inflammatory skin disorder. While corticosteroids offer a rapid response, their long‐term risks necessitate alternative treatments. Objective To compare the long‐term effectiveness of biologic therapies versus systemic corticosteroids in PG management. Methods A retrospective analysis of 15
R. Cascio Ingurgio   +8 more
wiley   +1 more source

Health Equity and Secukinumab for Severe Psoriasis in New Zealand

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives The only funded indication in New Zealand between October 2018 and April 2021 for the biologic secukinumab, an interleukin‐17A antibody, was severe psoriasis. This unique period of limited availability of secukinumab allowed the evaluation of who received it and health equity.
Anna Luo   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy